)
Lupin, India’s third-largest pharmaceuticals company by market capitalisation, is seeing a change at the helm. Today, the company’s board of directors appointed Vinita Gupta, daughter of Chairman D B Gupta, as chief executive officer, while her brother, Nilesh Gupta was appointed managing director.
Nilesh Gupta succeeds Kamal K Sharma, who has been promoted to the post of vice-chairman. The appointment is effective from 1st September, 2013
As chief executive of Lupin Pharmaceuticals, the company’s US subsidiary, Vinita Gupta, 45, played a key role in increasing Lupin’s revenue from the US market. Under her leadership, the company became the fifth-largest generic company in the US, with a revenue of $700 million. Vinita has a graduate degree in pharmacy from the University of Mumbai and a master’s degree in business administration from the J L Kellogg Graduate School of Management.
Currently, Nilesh Gupta is group president and executive director in the Lupin board. He is a chemical engineer from the University Department of Chemical Technology, Mumbai, and a graduate with honours from the Wharton School, University of Pennsylvania. He is responsible for all research and development activities — drug discovery, process research, formulation research and intellectual property management.
Last year, Samina Vaziralli, daughter of Cipla’s joint managing director M K Hamied, was inducted into the Cipla management.
